---
title: "The Misfits of Hong Kong: From Crypto Bets to Gold Safe Havens"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299025341.md"
description: "Uncategorized Hong Kong stocks reveal a polarized market reality. While IVD Medical pivoted to Ethereum for massive gains, Fufeng Group struggles with profit drops, leaving gold ETFs as the ultimate refuge amid broad silence."
datetime: "2026-09-15T09:18:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299025341.md)
  - [en](https://longbridge.com/en/news/299025341.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299025341.md)
generator: "portal-rs"
---

# The Misfits of Hong Kong: From Crypto Bets to Gold Safe Havens

Tracking the Hong Kong market often feels like navigating a fragmented bazaar. Beyond the tech heavyweights lies an eclectic mix of "uncategorized" assets—a strange combination of biopharma, legacy chemical producers, and gold ETFs. This matters because looking at these orphaned stocks reveals exactly how capital is behaving in the cracks of the market.

I'm told that recently, the biggest market swings haven't come from solid fundamentals, but from wild conceptual pivots. Take **IVD Medical Holding (1193.HK)**. Once a standard medical device distributor, the company decided to buy Ethereum as a reserve asset via HashKey Exchange. Riding the Real World Asset (RWA) tokenization wave, the stock surged over 400% in a single month recently. And yet... the underlying business is struggling, with the company reporting a net loss of RMB 70.49 million for mid-2026. The truth, as usual, is more complicated, with crypto hype temporarily masking operational weakness.

Elsewhere, legacy businesses and biotech startups are fighting their own battles. **Fufeng Group (1956.HK)**, the MSG giant, saw its mid-2026 profit plummet over 80% due to falling product prices, prompting a series of recent share buybacks. On the innovation front, **Well-sun Biopharma (2553.HK)** marked a regulatory milestone in August 2026 when its PD-L1/4-1BB bispecific antibody NDA was officially accepted.

Hovering above all this is a clear sense of underlying anxiety. The steady presence of the **SPDR Gold Trust (2848.HK)** highlights an ongoing flight to safety. When you look at the relative silence surrounding the rest of this cohort—companies like **Atour Group (6855.HK)**, **Shulan Health (2522.HK)**, **HKC (6687.HK)**, and **Boni Holding (434.HK)**, or even niche plays like **Jinhai Medical (2225.HK)** and **General Commemorative Coin Exchange (7656.HK)**—the market's wait-and-see approach becomes deafeningly obvious.

My view is: when the most exciting narrative in a sector is a healthcare distributor hoarding Ethereum, while the rest are either executing defensive buybacks or hiding in gold ETFs, it tells you everything you need to know about the current risk appetite. Good luck finding a straightforward fundamental play here.

*This article does not constitute investment advice.*

### Related Stocks

- [01193.HK](https://longbridge.com/en/quote/01193.HK.md)
- [01956.HK](https://longbridge.com/en/quote/01956.HK.md)
- [02553.HK](https://longbridge.com/en/quote/02553.HK.md)
- [02848.HK](https://longbridge.com/en/quote/02848.HK.md)
- [06855.HK](https://longbridge.com/en/quote/06855.HK.md)
- [02522.HK](https://longbridge.com/en/quote/02522.HK.md)
- [06687.HK](https://longbridge.com/en/quote/06687.HK.md)
- [00434.HK](https://longbridge.com/en/quote/00434.HK.md)
- [02225.HK](https://longbridge.com/en/quote/02225.HK.md)
- [07656.HK](https://longbridge.com/en/quote/07656.HK.md)

## Related News & Research

- [JST Group files next-day disclosure with HKEX announcing share buyback](https://longbridge.com/en/news/306263505.md)
- [JST Group Discloses Share Buyback in Next-Day Return to HKEX](https://longbridge.com/en/news/306105536.md)
- [JST Group Files HKEX Next Day Disclosure Return Announcing Share Buyback](https://longbridge.com/en/news/305962306.md)
- [JST Group Discloses Share Buyback in HKEX Next Day Return](https://longbridge.com/en/news/305804819.md)
- [Wenge AI Adds Google and Apple Sign-In Options for ScienceOra International Users](https://longbridge.com/en/news/306227628.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**